Page 24 - 分子轉譯影像中心季刊 IX
P. 24
討論與結論：
本實驗設計的6種正子放射性追蹤劑在LNCaP細胞上皆表現很高的親和性(4-
36nM)，並在LNCaP異種移植老鼠的腫瘤上有很高的吸收值(>5%ID/g)。此6種
68
新的正子放射性追蹤劑與目前臨床廣泛使用的PSMA影像探針:[ Ga]Ga-PSMA-
HBEDCC，和現行正在進行臨床試驗的放射性追蹤劑: 18 F-DCFPyL相比較， 18 F-
RPS-040和 F-RPS-041展示很高的腫瘤吸收(>10%ID/g)與很高的腫瘤/背景比
18
值和腫瘤/腎臟比值。本篇研究使用簡單放射合成方法得到高產率 F標誌PSMA
18
受體，並在體內體外試驗中皆得到很有希望的結果，使得此種新藥值得在臨床前
列腺癌正子影像上發展研究。
參考文獻：
1. Nikolopoulou A, Amor-Coarasa A, Kelly J, Vallabhajosula V,Babich J. Comparative
evaluation of 68Ga-labeled urea-based PSMA ligands in LNCaP tumor bearing mice.
J Nucl Med.2015;56(no. supplement 3):114.
2. Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC,Zimmerman CN, et al. 99mTc-
labeled small-molecule inhibitors of prostate-specific membrane antigen for
molecular imaging of prostate cancer. J Nucl Med. 2013;54:1369–76.
3. Maresca KP, Hillier SM, Femia FJ, Barone DKC, Joyal JL, Zimmerman CN, et al. A Series
of halogenated heterodimeric inhibitors of prostate specific membrane antigen
(PSMA) as radiolabeled probes for targeting prostate cancer. J Med
Chem.2009;52:347–57.
4. Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligand-targeted
cancer therapeutics and imaging agents. Nat Rev Drug Discov. 2015;14:203–19.
